NCT04679285

Completed

Minimal Residual Disease Evaluation on Cryopreserved Ovarian...

University Hospital, Lille Source

Compare

Other study identifiers

Sponsor study identifier

2020_12

Secondary identifiers

2020-A01513-36

OTHER · ID-RCB number,ANSM

Study Type

observational

Actual enrollment (reported)

9

Locations

1 country

Sites

1

Timeline

Study Start

April 26, 2021

Actual (reported)

Primary Completion

September 4, 2022

Actual (reported)

Study Completion

September 4, 2022

Actual (reported)

Brief Summary

Cryopreservation of ovarian cortex represents an option for fertility preservation in patients diagnosed with acute myeloid leukemia and requiring allogeneic stem cell transplantation. This pilot study aims to evaluate the minimal residual disease on ovarian fragments harvested before allogeneic stem cell transplantation at the time of complete remission.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Actual enrollment (reported): 9 participants
Study completion date: September 4, 2022
Actual (reported)
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

First Submitted
December 16, 2020
Actual (reported)
First Posted
December 22, 2020
Actual (reported)
Study Start
April 26, 2021
Actual (reported)
Primary Completion
September 4, 2022
Actual (reported)
Study Completion
September 4, 2022
Actual (reported)

Last Updated: December 23, 2025
Status Verified: December 2025
Last Update Submitted: December 17, 2025

Conditions

Acute Myeloid Leukemia

Keywords

Acute myeloid leukemiaFertility preservationOvarian cryopreservationMinimal residual disease

Outcome Measures

Primary Outcomes (1)

Percentage of patients without detectable MRD in ovarian tissue
Up to 6 months

Secondary Outcomes (1)

Percentage of patients with MRD detected in ovarian tissue and bone marrow.
Up to 1 month

Eligibility Criteria

Age2 Years - 40 Years

Sexfemale(Gender-based eligibility)

Healthy VolunteersNo

Age GroupsChild (0-17), Adult (18-64)

Sampling MethodNon-Probability Sample

Study Population

Patients aged 2 to 40 year-old, who present at least one molecular marker at acute myeloid leukemia diagnosis and who undergo ovarian cryopreservation for fertility preservation at the time of complete remission, before hematopoietic stem cell transplantation.

You may qualify if:

Sponsors & Collaborators

Saint-Louis Hospital, Paris, France
Othercollaborator
University Hospital, Lille
Otherlead
Canceropôle Nord Ouest

Study Sites (1)

CHU lille

Lille, 59037, France

Biospecimen

Retention: SAMPLES WITH DNA

Bone marrow, blood, ovarian fragments

MeSH Terms

Conditions

Leukemia, Myeloid, AcuteNeoplasm, Residual

Condition Hierarchy (Ancestors)

Leukemia, MyeloidLeukemiaNeoplasms by Histologic TypeNeoplasmsHematologic DiseasesHemic and Lymphatic DiseasesNeoplastic ProcessesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

Laurène Fenwarth, MD
University Hospital, Lille
PRINCIPAL INVESTIGATOR

Enrollment

9 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: CROSS SECTIONAL
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

December 16, 2020

First Posted

December 22, 2020

Study Start

April 26, 2021

Actual (reported)

NCT04777916

Prospective Non-interventional Study of Adult Patients With Acute Myeloid Leukemia (AML)

Recruiting

NCT04886206

Injection of Lymphocytes From Haplo-identical Donor Following Chemotherapy in Patients With High-risk Acute Myeloblastic Leukemia Not Eligible for an Allogeneic Hematopoietic Stem Cell Transplantation

Phase 1Unknown

NCT04822766

A Study Comparing Allogeneic Hematopoietic Cell Transplantation Versus Best Available Standard of Care Therapy in Elderly Patients With Acute Myeloid Leukemia

Not ApplicableActive Not Recruiting

NCT04641910

Validation Study of a New Cytokine-based Dynamic Stratification Based on FLt3 Ligand Plasma Concentration Kinetic Profile and IL-6 Concentration During Induction of Acute Myeloid Leukemia

Completed

NCT05304156

Single-cell Dynamic Profiling in Adults With Newly Diagnosed Acute Myeloid Leukemia Treated With Intensive Chemotherapy. A THEMA Study"

Unknown

NCT06565975

Characteristics and Outcomes of Acute Myeloid Leukemia (AML) Patients Treated With Oral-Azacitidine Maintenance Therapy in France

Completed

Patient diagnosed with AML

At least one molecular marker identified at AML diagnosis

Patients who undergo ovarian tissue cryopreservation for fertility preservation in complete remission, before hematopoietic stem cell transplantation.

You may not qualify if:

Other diagnostic
No marker available at AML diagnosis
No bone marrow/ovarian fragment available at the time of complete remission

Contact the study team to confirm eligibility.

Othercollaborator

Primary Completion

September 4, 2022

Actual (reported)

Study Completion

September 4, 2022

Actual (reported)

Last Updated

December 23, 2025

Record last verified: 2025-12

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT04679285
Data provider: ClinicalTrials.gov
Source updated: 2025-12-23
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:29:20 UTC

Locations

FR(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Biospecimen

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations